Marché mondial de la porphyrie aiguë intermittente – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse et taille du marché de la porphyrie aiguë intermittente

Le marché de la porphyrie aiguë intermittente (AIP) présente des défis et des opportunités uniques dans le segment des maladies rares des soins de santé. L'AIP est un trouble métabolique génétique caractérisé par des déficiences en enzymes essentielles à la production d'hème, entraînant l'accumulation de porphyrines et les symptômes aigus associés. Malgré sa rareté, le marché de l'AIP est stimulé par une sensibilisation et un diagnostic croissants des troubles génétiques , des progrès dans les technologies de diagnostic permettant une détection plus précoce et une population de patients croissante à l'échelle mondiale. Le marché de l'AIP se caractérise par des efforts de recherche continus visant à développer des thérapies ciblées et à améliorer les résultats des patients. Les collaborations entre les sociétés pharmaceutiques, les institutions universitaires et les prestataires de soins de santé sont essentielles pour faire progresser les options de traitement et élargir l'accès à des thérapies efficaces pour les patients atteints d'AIP dans le monde entier. À mesure que la sensibilisation augmente et que les capacités de diagnostic s'améliorent, le marché de l'AIP est susceptible de connaître une croissance et une innovation continues.

La taille du marché mondial de la porphyrie aiguë intermittente était évaluée à 4,35 milliards USD en 2023 et devrait atteindre 6,88 milliards USD d’ici 2031, avec un TCAC de 5,9 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l’épidémiologie des patients, l’analyse du pipeline, l’analyse des prix et le cadre réglementaire.

Portée du rapport et segmentation du marché       

Market Definition

Acute intermittent porphyria (AIP) is a rare genetic metabolic disorder characterized by deficiencies in enzymes involved in the production of heme, a crucial component of hemoglobin and other hemoproteins. This deficiency leads to the accumulation of porphyrins and their precursors in the body, particularly in the liver, which can result in acute attacks of symptoms such as severe abdominal pain, neurological disturbances, muscle weakness, and potentially life-threatening complications. AIP is inherited in an autosomal dominant manner, meaning that a person only needs to inherit one copy of the defective gene to develop the disorder.       

Acute Intermittent Porphyria Market Dynamics

Drivers

• Advancements in Diagnostic Technologies  

Continuous advancements in diagnostic technologies, such as genetic testing and biomarker identification, are pivotal in driving market growth for Acute Intermittent Porphyria (AIP). These technologies enable healthcare providers to detect genetic mutations and biomarkers associated with AIP more accurately and at earlier stages of the disease. Early diagnosis not only improves patient outcomes by enabling timely intervention but also supports the development and adoption of targeted therapies tailored to individual patient profiles. For instance, in 2021, research published on Pubmed highlighted new technological advancements focused on stabilizing the Hydroxymethylbilane Synthase gene (HMBS) and enhancing proteostasis in the human body to treat rare acute intermittent porphyria  The integration of advanced diagnostics into clinical practice enhances disease management strategies, reduces diagnostic uncertainties, and supports personalized treatment approaches, thereby contributing to the expansion of the AIP market.     

• Increasing Awareness and Diagnosis of Acute Intermittent Porphyria   

Rising awareness among healthcare professionals and patients about genetic disorders like Acute Intermittent Porphyria (AIP) is instrumental in driving higher diagnosis rates and expanding the patient pool. As awareness grows, more patients are likely to seek medical evaluation for symptoms suggestive of AIP, leading to earlier diagnoses and improved management of the disease. For instance, Recordati Rare Diseases Inc. is collaborating with the European Porphyria Network to develop patient and family information, enabling early symptom recognition and proactive measures to mitigate their impact. Enhanced collaboration between patient advocacy groups, healthcare organizations, and medical professionals further supports efforts to raise awareness and promote early detection, ultimately benefiting individuals affected by AIP and advancing market growth.

Opportunities

• Government Support for Research and Development in Rare Diseases     

Supportive government initiatives and funding for research and development in rare diseases, including Acute Intermittent Porphyria (AIP), play a crucial role in fostering innovation and advancing treatments and therapies. Government-backed research grants, tax incentives, and regulatory policies aimed at accelerating drug development and approval processes incentivize pharmaceutical companies and research institutions to invest in AIP research. Increased funding for clinical trials and collaborative research projects facilitates the exploration of novel therapeutic approaches and biomarker discovery, driving progress toward effective treatments for AIP, and creating new opportunities for the market.    

• Growing Healthcare Expenditure   

Increasing healthcare budgets enable healthcare systems to expand their capabilities in diagnosing, treating, and managing rare genetic disorders, supporting the development and adoption of innovative therapies. Healthcare expenditure growth is driven by rising demand for advanced medical technologies, personalized medicine approaches, and improved patient outcomes across diverse healthcare settings. As healthcare expenditures continue to rise, stakeholders in the AIP market can capitalize on opportunities to introduce new treatment modalities, improve patient care pathways, and enhance overall healthcare delivery for individuals affected by AIP. Escalating healthcare expenditure globally provides opportunities for greater investment in specialized treatments and management strategies for rare diseases like Acute Intermittent Porphyria (AIP).

Restraints/Challenges

• High Cost of Acute Intermittent Porphyria Treatment  

The high cost associated with specialized treatments and therapies for Acute Intermittent Porphyria (AIP) poses significant challenges and may limit access for patients, especially in regions with limited healthcare resources. Treatment expenses often include costly medications, recurrent hospitalizations, and specialized medical consultations, placing a financial burden on patients and healthcare systems alike. The affordability of AIP treatments becomes a critical concern, influencing patient access and adherence to recommended therapies and challenging the market growth. 

• Complexity in Acute Intermittent Porphyria Diagnosis    

Diagnosing Acute Intermittent Porphyria (AIP) can be challenging due to its nonspecific symptoms, which often overlap with other medical conditions. Patients may present with abdominal pain, neurological manifestations, and psychiatric symptoms that vary in severity and frequency, complicating the diagnostic process. Misdiagnosis or delayed diagnosis of AIP can lead to inappropriate treatments and prolonged suffering for patients. Improving diagnostic accuracy requires heightened awareness among healthcare providers, access to specialized diagnostic tests, and clinical guidelines that emphasize early recognition of AIP symptoms.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

Acute Intermittent Porphyria Market Scope

The market is segmented on the basis of type of diagnosis, treatment, and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Blood Test
• Urine Test
• DNA Test
• Serum Test

Treatment

• Gonadotropin-Releasing Hormone Analogues
• Prophylactic Hematin Infusions

End Users

• Hospitals
• Clinics
• Research Centers

Acute Intermittent Porphyria Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, type of diagnosis, treatment, and end users as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to its advanced healthcare technology encompassing sophisticated medical equipment, diagnostic tools, and treatment options. These resources enable effective management of conditions such as acute intermittent porphyria. The increasing number of patients with genetic metabolic disorders highlights a growing population in need of specialized medical care for conditions like acute intermittent porphyria. 

Asia-Pacific is expected to witness significant growth during the forecast period due to rapid adoption of advanced healthcare technologies. Healthcare providers in the region benefit from state-of-the-art medical innovations, such as advanced diagnostic tools, treatments, and surgical techniques. These advancements significantly bolster Asia-Pacific's capacity to diagnose and manage conditions like acute intermittent porphyria with greater precision and efficacy.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Acute Intermittent Porphyria Market Share Analysis

Le paysage concurrentiel du marché fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Certains des principaux acteurs opérant sur le marché sont :

• Siemens AG (Allemagne)
• Sonova Holding AG (Suisse)
• CR Bard, Inc. (États-Unis)
• Boston Scientific Corporation (États-Unis)
• Koninklijke Philips NV (Pays-Bas)
• Danaher Corporation (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• ARKRAY, Inc. (Japon)
• ACON Laboratories, Inc. (États-Unis)
• Nurotron Biotechnology Co. Ltd. (Chine)

SKU-18003